Core Insights - Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for prevalent retinal diseases [2] - The company will present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference, with management available for one-on-one meetings [1] Company Overview - Kalaris Therapeutics was founded by Dr. Napoleone Ferrara, known for his research that led to anti-VEGF therapy [2] - The company aims to address major unmet medical needs in retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) [2] Event Details - The presentation will take place on December 3, 2025, from 11:30 to 11:55 am ET at Florida Atlantic University, Boca Raton, FL [3] - Matthew Feinsod, Chief Medical Officer, will be the speaker at the event [3]

Summary of Kodiak Sciences Conference Call Company Overview - **Company**: Kodiak Sciences (NasdaqGM: KOD) - **Focus**: Pre-commercial retina-focused biotech company - **Key Asset**: KSI-101, developed for macular edema secondary to inflammation (MESI) [2][3] Industry Context - **Market Size**: The anti-VEGF market exceeds $15 billion [3] - **Competition**: Current agents like Eylea and Lucentis are considered Gen 1 agents, with newer agents like Eylea HD and Vabysmo termed Gen 1.5, showing only incremental improvements [8][9] Core Points and Arguments 1. **Pipeline Development**: - Kodiak has three phase three programs: KSI-101, tarcocimab, and KSI-501 [3][6] - KSI-101 is a bispecific protein targeting both IL-6 and VEGF, aimed at treating MESI [16][21] - Tarcocimab and KSI-501 are conjugates targeting retinal vascular diseases, with positive phase three data expected [5][11] 2. **Clinical Trials**: - Tarcocimab has three completed phase three studies (Beacon, GLO1, Daylight) with positive results, and GLO2 is ongoing [4][5] - KSI-501 is also expected to provide top-line data in the Daybreak study by mid-September [5][12] - KSI-101 is currently enrolling in the Peak and Pinnacle phase three studies, with expectations for top-line data in late 2026 [5][25] 3. **Scientific Innovation**: - Kodiak aims to develop biologics that provide high immediacy and durability, addressing unmet needs in the retinal disease market [10][15] - The company has shown that tarcocimab has a mean ocular half-life of 20 days, significantly longer than competitors [11] 4. **Market Opportunity**: - There is a strong unmet need for effective treatments in the retinal disease market, particularly for conditions like diabetic retinopathy and macular edema [10][14] - KSI-101 is positioned to potentially be a disease-modifying therapy for MESI, with a focus on dual inhibition of IL-6 and VEGF [18][21] 5. **Regulatory Pathway**: - Kodiak plans to file a Biologics License Application (BLA) for tarcocimab in mid-2027 based on positive data from ongoing studies [6][12] Additional Important Insights - **Patient Population**: Kodiak's studies include a broader range of patients compared to competitors, allowing for more inclusive treatment options [28][29] - **Safety Profile**: KSI-101 is designed to have a strong safety profile, differentiating it from steroid treatments [21] - **Future Directions**: Kodiak is considering expanding its research to include diabetic macular edema (DME) with either KSI-101 or KSI-501, depending on upcoming data [32][34] Conclusion Kodiak Sciences is positioned as a leading player in the retina-focused biotech space, with a robust pipeline and innovative approaches to treating retinal diseases. The upcoming clinical data and regulatory filings will be critical in determining the company's future success and market position.

AMD Disease Overview - AMD (Age-related Macular Degeneration) affects one in eight people 60 years or older and is the most common cause of blindness in developed countries [8] - An estimated 200 million people worldwide have AMD, projected to reach nearly 300 million by 2040 [8] - Wet AMD is characterized by abnormal blood vessel growth and leakage in the retina, damaging the macula and distorting central vision [7] Current Treatment & Limitations - Current gold standard treatment is anti-VEGF therapy, requiring direct eye injections every 4-6 weeks for 2 years or longer [16][23] - Anti-VEGF therapy, while effective in slowing vision loss and sometimes restoring sight, presents a significant treatment burden on patients, families, physicians, and the healthcare system [14][16][17] - Anti-VEGF drugs have a short half-life in the eye, necessitating repeated injections [17][18] Novel Drug Delivery System - The company is developing a biodegradable microsphere hydrogel composite system for sustained release of anti-VEGF drugs [19] - This system aims to maintain a relatively constant anti-VEGF level in the eye, potentially extending the duration between injections to 6-7 months [19][22] - The system is designed to be injectable using the same procedure, minimizing the need for physicians to adapt to new techniques [20] - Preclinical studies have demonstrated the safety and effectiveness of the drug delivery system [21]

Market Overview - The global branded anti-VEGF market for retinal neovascular/exudative diseases is approximately $14 billion in 2023 and is projected to grow to approximately $18 billion by 2029[8, 16, 24] - Branded anti-VEGF therapies accounted for approximately 70% of the global anti-VEGF units in retinal disease in 2023, while compounded bevacizumab accounted for approximately 30%[25] TH103 Development - TH103 is a fusion protein targeting VEGF, engineered for longer-lasting and increased anti-VEGF activity, invented by VEGF pioneer Dr Napoleone Ferrara[6, 8, 38] - Preclinical studies demonstrated TH103 achieved 100% inhibition of VEGF-induced endothelial cell proliferation in vitro, compared to 80% by aflibercept[57] - TH103 demonstrated increased retention in the retina compared to aflibercept at two weeks in rabbit retina cross-sections[64] - In a mouse laser CNV model, TH103 demonstrated increased duration of action in reducing mean CNV area after administration at Day -14 compared to aflibercept[72] Clinical Program & Intellectual Property - Kalaris received IND clearance from the FDA in June 2024 for a Phase 1 clinical trial of TH103 for nAMD[84] - Initial clinical data from the Phase 1 trial of TH103 for nAMD is expected in Q4 2025[8, 84, 86] - Kalaris holds US exclusivity for TH103 compositions of matter through the early 2040s[92]